Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Erika Ohashi"'
Publikováno v:
International Journal of Breast Cancer, Vol 2015 (2015)
Objective. To compare the real-world effectiveness of everolimus-based therapy and chemotherapy in postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative (HR+/HER2−) metastatic breast cancer (mBC). Met
Externí odkaz:
https://doaj.org/article/e254ee5eddb948ea899bc0af23180f33
Autor:
Kavita Sail, Pablo Martinez-Martin, Thomas S. Marshall, Dendy Macaulay, Fan Mu, Yash J. Jalundhwala, Erika Ohashi
Publikováno v:
Movement Disorders
Repisalud
Instituto de Salud Carlos III (ISCIII)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Parkinson's disease is a progressive, disabling neurodegenerative disorder associated with significant economic burden for patients and caregivers. The objective of this study was to compare the direct and indirect economic burden of Parkinson's pati
Publikováno v:
Journal of Leukocyte Biology. 92:1215-1225
G-CSF stimulates the expression of the chemokine MIP-2 in mature neutrophils by a direct transcriptional mechanism dependent upon STAT3. Neutrophil mobilization from the bone marrow is a critical aspect of the innate immune response, enabling a rapid
Publikováno v:
Clinical therapeutics. 38(4)
Purpose This review compared the real-world effectiveness of everolimus-based therapy versus endocrine monotherapy or chemotherapy in postmenopausal hormone receptor positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2−) metastat
Publikováno v:
Experimental Hematology & Oncology
Background Hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2−) is the most common type of metastatic breast cancer (mBC). While mBC patients generally have poor prognosis with limited progression-free survival (
Autor:
Peggy L. Lin, Erika Ohashi, Nanxin Li, Yanni Hao, James Signorovitch, Denise A. Yardley, Valerie Koo, Eric Q. Wu, Jipan Xie
Publikováno v:
Current medical research and opinion. 31(6)
Everolimus-based therapy and endocrine monotherapy are used among postmenopausal women with hormone receptor-positive human epidermal growth factor receptor-2 negative (HR+/HER2−) metastatic breast cancer (mBC) whose disease progressed or recurred
Autor:
Peggy L. Lin, Erika Ohashi, Caroline Kelley, Yanni Hao, Eric Q. Wu, James Signorovitch, Alexander R. Macalalad, Zhou Zhou
Publikováno v:
Value in Health. 18(3)
Publikováno v:
International Journal of Breast Cancer, Vol 2015 (2015)
International Journal of Breast Cancer
International Journal of Breast Cancer
Objective. To compare the real-world effectiveness of everolimus-based therapy and chemotherapy in postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative (HR+/HER2−) metastatic breast cancer (mBC).Meth
Publikováno v:
Electrochemistry. 74:149-152
A surface of gold electrode was modified with a self-assembled monolayer in order to protect the oxidation of ascorbic acid, which exists in biological fluid. The electrode was prepared by the modification with aqueous solution of 5-carboxypentanethi
Autor:
Alexander R. Macalalad, Erika Ohashi, Peggy L. Lin, Yanni Hao, Zhou Zhou, James Signorovitch, Eric Q. Wu, Caroline Kelley
Publikováno v:
Current medical research and opinion. 31(2)
Clinical guidelines prefer endocrine therapy (ET) as initial treatment for post-menopausal women with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC). Chemotherapy (CT) should b